AndreaBozzo/ceres-open-data-index huggingface dataset:
19th NCCAN Day Two Plenary

The 19th National Conference on Child Abuse and Neglect (NCCAN) was held from April 30 to May 2, 2014, in New Orleans, LA. Each day featured a plenary session on a specific topic. The day two plenary featured the presentation, "Why, When We Know So Much, Do We Do So Little? Overcoming Early Childhood Adversity," by Howard Spivak, M.D.; Nadine Burke Harris, M.D., M.P.H., F.A.A.P.; and Larry Adelman. Additionally, Parents Anonymous® and the National Alliance of Children's Trust and Prevention Funds presented awards.

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 528748: 1,3,5-Dithiazine, 4-butyl-2-mehyl-6-pentyl

Chemical compound data from PubChem database. IUPAC Name: 4-butyl-2-methyl-6-pentyl-1,3,5-dithiazinane. Molecular Formula: C13H27NS2. Molecular Weight: 261.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
The DAWN Report: Emergency Department Visits for Adverse Reactions Involving the Insomnia Medication Zolpidem

This Drug Abuse Warning Network (DAWN) short report looks at the estimated number of emergency room visits for adverse reactions involving involving the prescription sleep qie zolpidem for 2005 through 2010. The report focuses on gender, age groups and other pharmaceuticals such as pain relievers, other anti-anxiety and insomnia medications or alcohol taken with zolpidem.
Increased production of pro-inflammatory cytokines and enhanced T cell responses after activation of human dendritic cells with IL-1 and CD40 ligand

Background
          Various microbial, inflammatory and immune signals regulate the activation of dendritic cells (DC), determining their ability to interact with naïve T cells and to produce cytokines that direct T cell development. In particular, CD40L and IL-1 cooperatively activate DC to secrete high levels of IL-12. The immuno-stimulatory capacity of such DC is otherwise not well-defined prompting further characterization of the effects of IL-1 and family members on DC activation in comparison with other pro-inflammatory stimuli.
        
        
          Results
          Human DC co-activated in vitro by CD40L and IL-1β expressed numerous cytokine genes including IL-12β, IL-23 p19, IL-1β, IL-1α, IL-1Ra, IL-10, IL-6, IL-18 and IFN-γ. These DC produced high levels of IL-12 protein and appeared capable of producing IFN-γ. Potent CD4+ and CD8+ T cell-stimulatory properties were acquired by DC under conditions that also induced IL-12. Notably, these DC induced rapid differentiation of fluMP-specific CD8+ T cells. Molecules related to IL-1β, like IL-1α, co-induced IL-12 secretion whereas IL-18 did not. Conversely, the inhibitor IL-1Ra, produced endogenously by DC curtailed IL-12 production in response to CD40L.
        
        
          Conclusions
          IL-1 and IL-1Ra play a biologically-relevant role in the positive and negative regulation of DC activation. In conjunction with CD40L, IL-1 sends a powerful activation signal to DC that could be distinguished from other modes of activation. This signal enables the production of pro-inflammatory cytokines by DC, and enhances the differentiation of naïve T cells into effectors of type-1 cellular immune responses.
Treatment Episode Data Set (TEDS): 2014, National Discharges From Substance Abuse Treatment Services

This report presents data from the Treatment Episode Data Set (TEDS) for discharges from treatment in 2014. It is a companion to the reports Treatment Episode Data Set (TEDS): 2004-2014 National Admissions to Substance Abuse Treatment and Treatment Episode Data Set (TEDS): 2004-2014 State Admissions to Substance Abuse Treatment. These reports provide information on the demographic and substance abuse characteristics of substance abuse treatment admissions and discharges aged 12 and older in facilities that report to individual state administrative data systems. In addition, characteristics used to analyze changes from admission to discharge among the linked admission and discharge records are included. Primary substance of abuse, frequency of use, and employment status at admission are repeated in several tables. This is done so that characteristics at admission and discharge can be appropriately compared with each other and to ensure the inclusion of important data that might otherwise be overlooked.
Patent AT-E401250-T1: [Translated] DEVICE AND METHOD FOR PROVIDING ACTIVATED INDICATORS FOR GOODS LABELING

The active indicator provision process involves activating a temperature or time-sensitive indicator and then applying protective filter to it. The indicator passes through an activation unit (12) and a protective-filter application unit (66) downstream of the activation unit. The indicator may already have been attached to the protective filter. The device used in the process is also described.
Compound 525361: 2,3-Dimethyl-4,5-dithiaheptane

Chemical compound data from PubChem database. IUPAC Name: 2-(ethyldisulfanyl)-3-methylbutane. Molecular Formula: C7H16S2. Molecular Weight: 164.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526220: 1,2,3,4,6,9-Hexabromo-dibenzofuran

Chemical compound data from PubChem database. IUPAC Name: 1,2,3,4,6,9-hexabromodibenzofuran. Molecular Formula: C12H2Br6O. Molecular Weight: 641.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530101: 3-Methyluracil, TMS

Chemical compound data from PubChem database. IUPAC Name: 3-methyl-2-trimethylsilyloxypyrimidin-4-one. Molecular Formula: C8H14N2O2Si. Molecular Weight: 198.29. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525774: 2,4-Dimethyl-5-propyloxazole

Chemical compound data from PubChem database. IUPAC Name: 2,4-dimethyl-5-propyl-1,3-oxazole. Molecular Formula: C8H13NO. Molecular Weight: 139.19. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Table 6. Illicit Drug Use Other Than Marijuana in the Past Month, by Age Group and State: Percentages, Annual Averages Based on 2010 and 2011 NSDUHs

This report presents State estimates for measures of past month illicit drug use other than marijuana based on the combined 2010 and 2011 National Surveys on Drug Use and Health (NSDUHs). Resuts are provided by age group.
Compound 526890: 2-[2-(2-Pentoxyethoxy)ethoxy]ethyl trifluoroacetate

Chemical compound data from PubChem database. IUPAC Name: 2-[2-(2-pentoxyethoxy)ethoxy]ethyl 2,2,2-trifluoroacetate. Molecular Formula: C13H23F3O5. Molecular Weight: 316.31. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Morphological types of breast cancer in family members and multiple primary tumours: is morphology genetically determined?

Background
          We conducted the present study to determine whether breast cancer morphology is genetically determined.
        
        
          Methods
          Using the nationwide Swedish Family Cancer Database, which includes data on 10.2 million individuals and over 25,000 morphology-specific breast cancers, we followed morphological types in familial cancers between mothers and daughters and between sisters. Additionally, we recorded morphological data in women who presented with two primary breast cancers and in those who presented with an invasive and in situ breast cancer. We used kappa statistics to examine the association between genetics and morphology. A kappa value of 0 indicates that the process is random and a value of 1 indicates that it is completely determined (i.e. genetic); values between 0.40 and 0.60 are considered to indicate a moderately determined process.
        
        
          Results
          The study sample included a total of 25,730 first and 3394 second invasive breast cancers, and 2990 in situ breast cancers. Ductal, lobular, tubuloductal and comedo were the most common invasive types. We identified 164 mother-daughter pairs with breast cancer of a defined morphology, yielding a low kappa value of 0.08. Among 100 sister pairs the kappa value was 0.002. In individuals with two primary breast cancers the kappa values were 0.22 and 0.01 for two invasive and in situ-invasive pairs, respectively. However, for a tumour with a subsequent tumour detected in the contralateral breast less than 1 year later the kappa value was 0.47.
        
        
          Conclusion
          The data suggest that breast cancer morphology is not genetically determined. However, because of mixed morphologies and the overwhelming prevalence of ductal morphology, the results for rare morphologies should be interpreted with caution.
Compound 527314: Methyl 2-[4-methoxy-3-(trifluoromethyl)anilino]benzoate

Chemical compound data from PubChem database. IUPAC Name: methyl 2-[4-methoxy-3-(trifluoromethyl)anilino]benzoate. Molecular Formula: C16H14F3NO3. Molecular Weight: 325.28. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Percentage of Drivers and Front Seat Passengers Wearing Seat Belts, 2012 & 2014, Region 8 - Denver

Source for 2012 national data: National Occupant Protection Use Survey (NOPUS), 2012. Source for 2014 national data: National Occupant Protection Use Survey (NOPUS), 2014.  Source for 2012 state data: State Observational Survey of Seat Belt Use, 2012. Source for 2014 state data: Seat Belt Use in 2014- Use Rates in the States and Territories
Compound 525785: 4-Ethyl-2-methyloxazole

Chemical compound data from PubChem database. IUPAC Name: 4-ethyl-2-methyl-1,3-oxazole. Molecular Formula: C6H9NO. Molecular Weight: 111.14. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529786: Benzoic acid, 2-hydroxy, 3,5-bis-(trifluoromethyl)phenylmethyl ester

Chemical compound data from PubChem database. IUPAC Name: [3,5-bis(trifluoromethyl)phenyl]methyl 2-hydroxybenzoate. Molecular Formula: C16H10F6O3. Molecular Weight: 364.24. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
AFCARS Report #21

This report provides preliminary estimates of AFCARS data for FY 2013. Preliminary reports of AFCARS data include data received by September 30 for the report period ending March 31 and by March 31 for the report period ending September 30. This generally encompasses the required data submissions and submission of corrected data by States to avoid possible financial penalties.

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 528382: 2,6-Dichloro-4-hydroxybenzaldehyde

Chemical compound data from PubChem database. IUPAC Name: 2,6-dichloro-4-hydroxybenzaldehyde. Molecular Formula: C7H4Cl2O2. Molecular Weight: 191.01. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401841-T1: [Translated] AUDITORIAL ossicle prosthesis with elastic swivel joint

An ossicle prosthesis (10) that replaces or bridges component(s) or parts of a component of the ossicular chain, comprises a rotary joint between two fastening elements (11, 12) comprising a silicone or polytetrafluoroethylene receiving part (13) in which a metal rotary element (14) fixedly connected with a metal longitudinal shank (16) that connects the two fastening elements is hingedly supported. The elastic plastic receiving part is rigidly connected with first fastening element. It comprises a cavity that encloses at least half of the surface of the rotary element in its installed state. An ossicle prosthesis that replaces or bridges component(s) or parts of a component of the ossicular chain, comprises a first fastening element at one end designed as a top plate for mechanical connection with the tympanic membrane; a second fastening element at the other end for mechanical connection with a component or parts of the ossicular chain or with the inner ear; and a rotary joint between the two fastening elements comprising a silicone or polytetrafluoroethylene receiving part in which a metal rotary element fixedly connected with a metal longitudinal shank that connects the two fastening elements is hingedly supported. The receiving part is made of an elastic plastic. It is rigidly connected with the first fastening element, and comprises a cavity shaped in such a way that when in an installed state, it encloses at least half of the surface of the rotary element.
Funding source, trial outcome and reporting quality: are they related? Results of a pilot study

Background
          There has been increasing concern regarding the potential effects of the commercialization of research.
        
        
          Methods
          In order to examine the relationships between funding source, trial outcome and reporting quality, recent issues of five peer-reviewed, high impact factor, general medical journals were hand-searched to identify a sample of 100 randomized controlled trials (20 trials/journal). Relevant data, including funding source (industry/not-for-profit/mixed/not reported) and statistical significance of primary outcome (favouring new treatment/favouring conventional treatment/neutral/unclear), were abstracted. Quality scores were assigned using the Jadad scale and the adequacy of allocation concealment.
        
        
          Results
          Sixty-six percent of trials received some industry funding. Trial outcome was not associated with funding source (p= .461). There was a preponderance of favourable statistical conclusions among published trials with 67% reporting results that favored a new treatment whereas 6% favoured the conventional treatment. Quality scores were not associated with funding source or trial outcome.
        
        
          Conclusions
          It is not known whether the absence of significant associations between funding source, trial outcome and reporting quality reflects a true absence of an association or is an artefact of inadequate statistical power, reliance on voluntary disclosure of funding information, a focus on trials recently published in the top medical journals, or some combination thereof. Continued and expanded monitoring of potential conflicts is recommended, particularly in light of new guidelines for disclosure that have been endorsed by the ICMJE.
Clindamycin phosphate and tretinoin gel 1.2%/0.025%

Clindamycin Phosphate and Tretinoin Gel 1.2%/0.025% is a prescription topical medication combining an antibiotic (clindamycin) to fight acne-causing bacteria and a retinoid (tretinoin) to unclog pores and promote skin renewal. Apply once daily to affected areas for acne treatment. Available in 30g or 60g tubes from Encube Ethicals, Inc. This information was generated using AI and is provided for informational and research purposes only.
NNDSS - Table II. Chlamydia to Coccidioidomycosis

NNDSS - Table II. Chlamydia to Coccidioidomycosis - 2017.  In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data.  Data on United States exclude counts from US territories.

Note:
These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. 

Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. 

Footnotes:
 C.N.M.I.: Commonwealth of Northern Mariana Islands. 

U: Unavailable. —: No reported cases. N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. 

* Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions. 

† Case counts for reporting year 2017 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for tuberculosis are displayed in Table IV, which appears quarterly.
AB Registration Completion List

Access Data Dictionary Here - <a href="https://www.cms.gov/CCIIO/Programs-and-Initiatives/Health-Insurance-Marketplaces/Downloads/62416-AB-Registration-Completion-List-Data-Dictionary-Web_v1.pdf">Data Dictionary (PDF)</a> Access Lines of Authority Here - <a href="/AB-NIPR-Health-Line-Of-Authority">NIPR Health Line of Authority</a>
Patent AT-E399834-T1: [Translated] USE OF 2,6-DI-TERT-BUTYL-P-CRESOL TO INCREASE THE STORAGE STABILITY OF BIODIESEL

A process for the improving the storage stability of biodiesel comprises dosing in a stock solution (I), comprising 15-60 wt.% 2,4-di-tert-butylhydroxy toluene (BHT) dissolved in biodiesel, to the biodiesel at a concentration of 0.005-2 wt.% BHT (with respect to the total solution of biodiesel). Independent claims are also included for: (1) the stock solution (I) and; (2) a process for the production of the stock solution (I), optionally containing other additives by the addition of liquid BHT to biodiesel at 70-120 [deg]C with stirring to a concentration of 15-60 wt.%.
Compound 527992: Propanoic acid, 2,2-dichloro-, decyl ester

Chemical compound data from PubChem database. IUPAC Name: decyl 2,2-dichloropropanoate. Molecular Formula: C13H24Cl2O2. Molecular Weight: 283.2. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Percutaneous tracheostomy: comparison of Ciaglia and Griggs
		  techniques

Background:
          Although the standard tracheostomy described in 1909 by Jackson
				has been extensively used in critical patients, a more simple procedure that
				can be performed at the bedside is needed. Since 1957 several different types
				of percutaneous tracheostomy technique have been described. The purpose of the
				present study was to compare two bedside percutaneous tracheostomy techniques:
				percutaneous dilatational tracheostomy (PDT) and the guidewire dilating forceps
				(GWDF).
        
        
          Materials and methods:
          A prospective study in two medical/surgical intensive care units
				(ICUs) was carried out. Sixty-three critically ill patients who required
				endotracheal intubation for longer than 15 days were consecutively selected to
				undergo PDT (25 patients) or GWDF (38 patients) technique. Intraoperative and
				postoperative complications were recorded.
        
        
          Results:
          Age (mean ± standard error) was 63 ± 1.1 years. The
				patients had been mechanically ventilated for an average of 19.8 ± 1.2
				days. The GWDF technique was significantly faster than PDT technique
				(P = 0.02). Fifteen complications occurred in 10 out of 63 (15%)
				patients. They were as follows: tracheal tear (one patient in each group; in
				one case this was due to false passage); transient hypotension (one patient in
				the PDT group and two patients in the GWDF group); atelectasis (one patient in
				the PDT group); and haemorrhage (one patient in the PDT group and three
				patients in the GWDF group). In both patients with tracheal tear, reduced
				arterial oxygen saturation (SaO2) with concomitant subcutaneous
				emphysema ensued.
        
        
          Conclusion:
          We found no statistical differences between complications with
				both techniques. The surgical time required for the GWDF technique was less
				than that for PDT.
Compound 529216: Cyclohexanol, DMTBS

Chemical compound data from PubChem database. IUPAC Name: tert-butyl-cyclohexyloxy-dimethylsilane. Molecular Formula: C12H26OSi. Molecular Weight: 214.42. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Haloperidol decanoate

Haloperidol Decanoate is a generic injectable antipsychotic medication used to treat certain mental health conditions like schizophrenia. It comes in strengths of 50 mg/mL and 100 mg/mL, administered via intramuscular injection. Manufactured by Caplin Steriles Limited under FDA application ANDA219168. This information was generated using AI and is provided for informational and research purposes only.
Patent AT-E400177-T1: [Translated] HERBICIDAL COMPOSITION

The present invention relates to surfactant systems and in particular herbicidal compositions comprising a water soluble herbicide and/or a salt thereof and a surfactant system, wherein the surfactant system comprises at least two surfactants selected from the group consisting of: i) alkyldiamine tetraalkoxylate surfactants; ii) N-alkyl alkyldiamine trialkoxylate surfactants; and iii) phosphated alcohol alkoxylate surfactants.
Compound 529073: 1H-Pyrrole, 2-butyl-1-methyl

Chemical compound data from PubChem database. IUPAC Name: 2-butyl-1-methylpyrrole. Molecular Formula: C9H15N. Molecular Weight: 137.22. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 527032: Chrysanthenol

Chemical compound data from PubChem database. IUPAC Name: 2,7,7-trimethylbicyclo[3.1.1]hept-2-en-6-ol. Molecular Formula: C10H16O. Molecular Weight: 152.23. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525371: 2,4,5-Trimethyl-3-thiahexane

Chemical compound data from PubChem database. IUPAC Name: 2-methyl-3-propan-2-ylsulfanylbutane. Molecular Formula: C8H18S. Molecular Weight: 146.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526706: Perfluoro-pentan ethioic acid S-propyl ester

Chemical compound data from PubChem database. IUPAC Name: S-propyl 2,2,3,3,4,4,5,5,5-nonafluoropentanethioate. Molecular Formula: C8H7F9OS. Molecular Weight: 322.19. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.